AstraZeneca grows faster than expected but maintains guidance

AstraZeneca PLC reported robust third-quarter 2025 results, surpassing analyst expectations with revenues of $15.19 billion, up 12% year-over-year, and core earnings per share climbing 14% to $2.38. The pharmaceutical giant highlighted strong underlying momentum across all therapy areas, including significant growth in oncology and respiratory segments, and an 'unprecedented' 16 positive Phase III trials this year. Despite this strong performance, the company reiterated its full-year 2025 guidance for high single-digit revenue growth and low double-digit core EPS growth, signaling confidence in sustained future performance through 2026 and towards its 2030 ambition.

Analysis

AstraZeneca (AZN) reported a robust third quarter 2025, exceeding analyst expectations with revenues of $15.19 billion, a 12% year-over-year increase, and core earnings per share climbing 14% to $2.38. This performance surpassed consensus forecasts of $14.8 billion and $2.30 respectively, driven by strong underlying momentum across all therapy areas, with nine-month revenue also growing 11% to $43.24 billion.

Key growth drivers included a 16% rise in oncology and a 13% increase in the respiratory and immunology segments, underscoring broad-based strength. CEO Pascal Soriot highlighted an "unprecedented" 16 positive Phase III trials this year, including significant advancements in hypertension and breast cancer treatments, which de-risk future growth and support the company's long-term strategic objectives.

Despite the strong beat, AstraZeneca reiterated its full-year 2025 guidance for high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates. This consistent outlook, coupled with management's confidence in sustaining growth through 2026 and achieving its 2030 ambition, suggests a predictable and well-managed growth trajectory, further supported by the 'most favoured nation' drug pricing agreement in the US.

Key Decisions for Investors

• Investors should consider the strong Q3 beat and robust pipeline as indicators of sustained fundamental strength for AstraZeneca, supporting a positive long-term outlook.
• Monitor the successful commercialization of the 16 positive Phase III trials, as these will be crucial for delivering on the 2026 and 2030 growth ambitions.
• While full-year guidance was maintained, the consistent outperformance suggests potential for future upward revisions, warranting close attention to upcoming reports and management commentary.